Welcome to our dedicated page for Cardiff Lexingto news (Ticker: CDIX), a resource for investors and traders seeking the latest updates and insights on Cardiff Lexingto stock.
Cardiff Lexington Corporation reports operating and capital-market developments for a healthcare services holding company focused on orthopedic, spine and pain-management platforms. Its current revenue is derived from Nova Ortho and Spine, which operates regional specialty and ancillary orthopedic care centers in Florida and Georgia that provide diagnostic services, surgical services, primary care evaluations, interventional pain management and specialty consultations for traumatic injury patients.
Recurring updates include financial results, patient-volume and procedure mix, facility and clinician additions, activity at Nova Ortho and Spine locations, acquisition strategy for orthopedic practices and related healthcare assets, OTC market status, reverse stock split actions, registration-statement activity and board governance changes.
Cardiff Lexington (OTCQX:CDIX) announced that subsidiary Nova Ortho and Spine has opened a new 2,975-square-foot medical office in Stuart, Florida. The clinic, on NW Federal Highway, expands Nova’s orthopedic, spine, and musculoskeletal care network along Florida’s growing Treasure Coast, serving Martin and St. Lucie County communities exceeding 650,000 residents.
Cardiff Lexington (OTCQX:CDIX) reported first quarter 2026 results for the period ended March 31, 2026. Revenue was $2.2 million versus $2.9 million a year ago, with gross profit of $1.3 million (59.3% margin).
Operating expenses rose to $1.8 million, including $664,000 of share-based compensation. The company reported a loss from continuing operations of $511,000 and a net loss of $3.1 million, including $1.9 million of interest expense. Adjusted EBITDA was $164,000. Cash was $684,000 and total assets increased 4.1% to $30.3 million. Management highlighted expansion of Nova Ortho and Spine locations and an upgrade to the OTCQX market. A conference call is scheduled for May 19, 2026, at 11:00 a.m. Eastern Time.
Cardiff Lexington (OTCQX:CDIX) will release first quarter 2026 financial and operating results on Tuesday, May 19, 2026, before market events, and host an investor conference call at 11:00 a.m. ET.
The call offers phone dial-in, webcast with slide deck, and replay access through June 2, 2026.
Cardiff Lexington (OTCQX:CDIX) was approved to trade on the OTCQX Best Market effective April 9, 2026, continuing under symbol CDIX. The upgrade highlights enhanced transparency, governance and a step toward a potential uplisting to a national exchange.
For FY2025 the company reported $11.5M revenue (+39.5% vs 2024), $7.2M gross profit (62.5% margin), $1.1M operating income (9.5% margin) and $29.1M total assets (+21.6%). Management cites working capital constraints as the primary limit on utilization and plans capital formation to scale operations and accelerate AR conversion.
Cardiff Lexington (OTCQB: CDIX) reported full year 2025 results: revenue $11.5M (up 39.5% YoY) and gross profit $7.2M (62.5% margin). Operating income was $1.1M while net loss was $(5.5M) due largely to $6.8M interest expense. The company executed a 1-for-3 reverse split and announced a March 16, 2026 investor webcast.
Management cited higher patient volumes, a shift to higher-value surgical procedures, expanded operations in Florida and Georgia, and talent additions to support growth and a planned uplisting.
Cardiff Lexington (OTCQB: CDIX) will release its fourth quarter and full year 2025 financial and operating results and host a conference call on Monday, March 16, 2026 at 11:00 am ET.
Shareholders can join via dial-in or webcast; a slide deck and an online replay (available through March 30, 2026) will be posted on the company's Investor Relations site.
Cardiff Lexington (OTCQB: CDIX) subsidiary Nova Ortho and Spine expanded its Florida clinical team on February 26, 2026 by hiring two procedurally trained nurse practitioners to support rising patient volume across Orlando and southeastern Florida.
The hires—Catherine Amanda Kelly, MSN, APRN, FNP-BC, and Ashley Logan, APRN-BC—bring combined procedural, neurosurgery, orthopedic surgery and pain management experience intended to improve operational efficiency, safety and patient satisfaction.
Cardiff Lexington Corporation (OTCQB:CDIXD / intends Nasdaq: CDIX) filed a registration statement on Form S-1 on December 15, 2025 for a proposed initial public offering of common stock and announced plans to uplist to Nasdaq Capital Market under the symbol CDIX. The company has engaged R. F. Lafferty & Co., Inc. as sole bookrunning manager to advise on market strategy, capital formation, valuation, investor positioning, and regulatory readiness. The number of shares and price range are not yet determined; the offering is subject to SEC effectiveness, Nasdaq approval, and market conditions.
Cardiff Lexington (OTCQB:CDIX) announced a 1-for-3 reverse stock split effective 12:01 a.m. ET on January 12, 2026. Every three pre-split shares were combined into one post-split share; fractional shares were not issued and were rounded up to the nearest whole share. The par value remained $0.001 and unchanged. The company’s common stock will trade on a split-adjusted basis on the OTCQB today, and the ticker will temporarily change to CDIXD for 20 trading days including the effective date. The stated purpose is to support compliance with Nasdaq Capital Market minimum bid price requirements. Post-split CUSIP is 14146R700.
Cardiff Lexington (OTCQB: CDIX) announced that long-serving Chairman Daniel Thompson will retire effective December 31, 2025 after 25 years of service. Alex Cunningham, President and Chief Executive Officer, will succeed Thompson as Chairman and assume the additional role immediately upon retirement.
The release says the company is positioned for further growth, highlights expansion of its operating subsidiary Nova Ortho and Spine in 2025, and cites a targeted plan to uplist the stock to a major US exchange to broaden investor visibility.